Acadia Hit With Securities Suit Over Drug Linked To Deaths
By Bonnie Eslinger ( July 20, 2018, 10:09 PM EDT) -- An Acadia Pharmaceuticals Inc. shareholder slapped the biopharmaceutical company with a putative securities fraud class action in California federal court Thursday, claiming the company inflated its stock price by hiding safety risks and downplaying reports of deaths connected to its treatment for hallucinations and delusions....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.